In this article, we will discuss the 11 Best Cancer Stocks to Invest In Now.
Pharmaceutical companies are a blend of defensive income plays and growth opportunities. They deliver stable earnings and returns as demand for medicines, vaccines, and treatments for chronic diseases remains steady regardless of the prevailing economic cycle. That’s evident in the S&P 500 Pharmaceutical index, which is already up by more than 6%, outpacing the broader S&P 500 index, which is up by a little over 1%.
The oncology segment of the pharmaceutical sector is one of the fastest-growing, driven by the rising prevalence of cancer and advancements in targeted therapies and immunotherapies. According to Allied Market Research, the cancer drugs market is growing at a 7.2% compound annual growth rate and is projected to reach $335.2 billion by 2032.
The oncology market is poised for accelerated growth, driven by the rising incidence of cancer in ageing societies, against a backdrop of changing lifestyles and environmental factors. For starters, demand for breast cancer drugs in the US is projected to reach $6.6 billion by 2036, reflecting 5.6% growth. The robust growth comes amid high treatment penetration, established screening programs, and long-term maintenance therapy use.
Therefore, the long-term outlook for cancer drug stocks remains positive, driven by structural market growth and innovation. With that in mind, let’s take a look at some of the best cancer stocks to invest in now.
Our Methodology
To compile a list of the Best Cancer Stocks to invest in now, we scanned Cancer research ETFs, such as the Range Cancer Therapeutics ETF (CNCR) and Tema Oncology ETF (CANC). We settled on stocks with strong analyst conviction and upside potential of more than 10%. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Best Cancer Stocks to Invest In Now
11. AbbVie Inc. (NYSE:ABBV)
AbbVie (NYSE:ABBV) is one of the best cancer stocks to invest in now. On February 23, AbbVie (NYSE: ABBV) announced plans to invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities. The new state-of-the-art facilities at the Illinois campus are to integrate advanced manufacturing technologies with artificial intelligence.
Artificial intelligence integration is part of AbbVie’s push to support and accelerate the development of next-generation neurosciences and obesity medications. Construction of the facilities is scheduled to begin in spring 2026 and come online in 2029. The construction of the state-of-the-art facility is part of the company’s $100 billion commitment towards research and development in the US.
“By strengthening our U.S. manufacturing capabilities, we are well-positioned to support our investment in innovation and enhance our ability to deliver next-generation medicines to patients,” said Robert A. Michael, chairman and chief executive officer, AbbVie.
AbbVie has already reiterated its plans to expand its manufacturing capabilities and capacity in the US. It has already broken ground on the first phase of the investment, with plans for a new chemical synthesis facility that will enable the return of API production for select neuroscience, immunology, and oncology products from Europe and Asia to the U.S.
AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company focused on discovering and developing targeted therapies for blood cancers and solid tumors. Its oncology portfolio and research pipeline heavily feature antibody-drug conjugates (ADCs), targeted protein degradation, CAR-T cell therapies, and bispecific antibodies.
10. Revolution Medicines, Inc. (NASDAQ:RVMD)
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best cancer stocks to invest in now. On February 26, Revolution Medicines, Inc. (NASDAQ:RVMD) CEO Mark A. Goldsmith reiterated that the company has made significant progress in developing a broad portfolio of RAS(ON) inhibitors across multiple disease settings.
Daraxonrasib, a pioneering RAS(ON) multi-selective inhibitor, has already shown an unprecedented clinical profile in various combinations. Consequently, the company is enrolling patients in the US for a Phase 3 trial of RASolve 301 in Non-Small Cell Lung Cancer (NSCLC).
On the other hand, Zoldonrasib, an innovative RAS(ON) G12D-selective covalent inhibitor, has shown a highly differentiated safety and tolerability profile.
“We expect a pivotal readout from RASolute 302 in the first half of 2026, which represents an important milestone for daraxonrasib, for patients with pancreatic cancer, and for our RAS(ON)-targeting strategy overall,” Goldsmith said.
Revolution Medicines exited 2025 in a strong financial position with $2 billion in cash, cash equivalents, and marketable securities. Research and development expenses surged to $294.9 million in the fourth quarter of 2025 from $188.1 million in the fourth quarter of 2024. The increase was driven by higher clinical trial and manufacturing expenses for daraxonrasib, zoldonrasib, and elironrasib. Full-year R&D expense totaled $987.3 million compared to $592.2 million in 2024
Net loss in the fourth quarter nearly doubled to $364.9 million, compared with $194.6 million in the same quarter of the prior year. The full-year 2025 net loss came in at $1.1 billion, compared to $600.1 million in 2024.
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage oncology company focused on discovering and developing targeted therapies for RAS-addicted cancers, which represent roughly 30% of new cancer diagnoses.
9. Arvinas, Inc. (NASDAQ:ARVN)
Arvinas Inc. (NASDAQ:ARVN) is one of the best cancer stocks to invest in now. On February 24, Arvinas Inc. (NASDAQ:ARVN) delivered solid fourth-quarter and full-year results that affirmed progress across pipeline development.
During the year, the company submitted its first new drug application, setting the stage for potential FDA approval of a PROTAC degrader. The company has already presented topline results for ARV-806, affirming robust and differentiated activity in models of KRAS G12D-mutated cancer. It is also progressing with dose escalation in the Phase 1 trial of ARV-393 in patients with non-Hodgkin’s lymphoma (NHL).393.
“With four ongoing clinical trials across our oncology and neurology portfolios, including the recently initiated first-in-human trial of our polyQ-AR degrader, ARV-027, we believe we have the potential to bring truly differentiated treatments to millions of patients in areas of significant unmet medical need,” said Randy Teel, Ph.D., President and CEO of Arvinas
Full year 2025 revenue came in at $262.6 million, down from $263.4 million a year ago. Fourth quarter revenue dropped to $9.5 million compared to $59.2 million in the same quarter of the prior year. The decrease was attributed to lower revenue from the Novartis license agreement.
Arvinas, Inc. (NASDAQ:ARVN) is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapies that degrade disease-causing proteins rather than just inhibiting them. Utilizing its proprietary PROTAC® (Proteolysis-Targeting Chimera) platform, the company targets “undruggable” proteins to treat serious, debilitating diseases, including prostate and breast cancers, as well as neurodegenerative disorders.
8. Guardant Health, Inc. (NASDAQ:GH)
Guardant Health Inc. (NASDAQ:GH) is one of the best cancer stocks to invest in now. On February 23, Guardant Health Inc. (NASDAQ:GH) completed the acquisition of the health technology company MetaSight Diagnostics. The $149 million acquisition comes as the company gears up for revenue growth in 2026.
With the acquisition, Guardant Health is to gain access to a range of next-generation liquid biopsies designed for the early detection of chronic and acute diseases, including cancer. Guardant is handing over $59 million in advance payments and has pledged up to $90 million in potential regulatory and commercial milestone payments.
MetaSight has carved a niche in developing next-generation diagnostics platforms using computational biology and advanced data analysis to identify disease signals in blood samples. Its acquisition will help strengthen Guardant Health’s research pipeline and expand its precision medicine capabilities.
The acquisition comes when Guardant Health is experiencing robust revenue growth with total revenue soaring 33% year over year in 2025 to $982 million. The increase was driven by growth in the oncology division, where revenue was up 26% to $683.6 million. For 2026, the company projects revenue growth of 27% to 30%, to a range of $1.25 billion to $1.28 billion.
Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company that develops liquid biopsy-based tests to detect cancer early, monitor recurrence, and guide personalized treatment selection. It provides comprehensive, non-invasive genomic profiling for patients with advanced or early-stage cancer.
7. Cogent Biosciences Inc. (NASDAQ:COGT)
Cogent Biosciences Inc. (NASDAQ:COGT) is one of the best cancer stocks to invest in now. On February 17, CEO Andrew Robbins reiterated that Cogent Biosciences Inc. (NASDAQ:COGT) has started 2026 with tremendous momentum backed by multiple value-creating regulatory catalysts.
In January, the US Food and Drug Administration accepted the company’s PEAK New Drug Application for bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST). Consequently, the company submitted to the FDA, having already secured Breakthrough Therapy Designation.
The slate of positive regulatory milestones comes on the candidate drug showing clear clinical benefit across all symptom domains. Cogent Biosciences is on the cusp of launching bezuclastinib in the second half of 2026, awaiting FDA approval.
Six Abstracts from the SUMMIT trial of bezuclastinib in patients with Non-Advanced Systemic Mastocytosis (NonAdvSM) have already been accepted for presentation at the 2026 AAAAI annual meeting.
Cogent Biosciences exited 2025 with $900.8 million in cash equivalents and marketable securities, having repaid $54.8 million of long-term debt in the fourth quarter. Research and development expenses increased to $75.6 million in the fourth quarter of 2025 from $62 million in the fourth quarter of 2024.
On the other hand, full-year R&D totaled $269.8 million, up from $232.7 million in 2024. Net loss widened to $102.5 million in the fourth quarter and to $328.9 million for the full year 2025, compared to $67.9 million and $255.9 million for the fourth quarter and full year 2024, respectively .
Cogent Biosciences Inc. (NASDAQ:COGT) is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. Their primary drug candidate, bezuclastinib (CGT9486), is a potent, selective inhibitor designed to treat systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST) by targeting the KIT D816V mutation.
6. Immunome, Inc. (NASDAQ:IMNM)
Immunome, Inc. (NASDAQ:IMNM) is one of the best cancer stocks to invest in now. On February 14, Immunome, Inc. (NASDAQ:IMNM) CEO and Chairman Clay Siegall reiterated heightened focus on building an oncology-focused pipeline centered on cell-surface-targeting agents and small molecules.
The ultimate goal is to develop a targeted oncology platform for small molecules that can overcome resistance and enable bystander activity. The remarks come on the company delivering top-line Phase 3 results for Varegacestat in desmoid tumors. The company is in the process of filing a New Drug Application as it sets its sights on a $1 billion market opportunity, targeting the over 3,000 patients treated annually.
Immunome also plans to submit three additional INDs this year targeting solid tumor programs. The push comes as the company’s radioligand therapy, which delivers radiation directly to tumors, receives FDA clearance. It is poised to start a clinical trial soon.
Immunome, Inc. (NASDAQ:IMNM) is a clinical-stage biotechnology company focused on discovering and developing first-in-class targeted therapies for oncology, primarily using antibody-drug conjugate (ADC) technology. They use a proprietary, memory B cell-based discovery engine to identify novel antibodies that treat cancers.
5. Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)
Syndax Pharmaceuticals (NASDAQ:SNDX) is one of the best cancer stocks to invest in now. On February 15, at the Guggenheim biotech conference, Chief Executive Officer Michael Metzger reiterated that Syndax Pharmaceuticals (NASDAQ:SNDX) started 2026 on a strong footing, going by the commercial performance of two key marketed products. In addition, the company is making significant progress on clinical and lifecycle milestones.
The company generated $125 million in annual net sales for Revuforj and $152 million for Niktimvo in the first 11 months. Consequently, the products are showing quarter-over-quarter sales growth. Revuforj’s revenue growth is driven by continued penetration in its labeled indication for KMT2A-rearranged acute myeloid leukemia.
In addition, the company is staring at a tremendous opportunity with Niktimvo in chronic GVHD, targeting 6,500 patients that could expand to about 17,000. Consequently, the company could generate up to $1 billion in third-line plus sales. Syndax has a strategic collaboration with Incyte to co-promote the product.
Syndax Pharmaceuticals (NASDAQ:SNDX) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative, first-in-class, targeted therapies for cancer, particularly acute leukemia and chronic graft-versus-host disease (cGVHD). They are known for FDA-approved drugs Revuforj (revumenib) and Niktimvo (axatilimab-csfr).
4. Schrödinger, Inc. (NASDAQ:SDGR)
Schrodinger Inc. (NASDAQ:SDGR) is one of the best cancer stocks to invest in now. On February 25, Schrodinger Inc. (NASDAQ:SDGR) delivered solid fourth-quarter and full-year 2025 results characterized by robust revenue growth. The company also announced it is accelerating its transition to a licensing model to establish a more predictable, higher-visibility revenue stream.
Full-year revenue was up by 23.3% to $255.9 million, driven by a 10.6% increase in software revenue. Drug discovery revenue more than doubled to $56.4 million from $27.2 million in the prior year. However, fourth-quarter revenue was down 1.2% year over year to $87.2 million, as software revenue fell 13% to $69.3 million. Drug discovery in the quarter more than doubled to $18 million compared to $8.7 million in the same quarter of the prior year.
“Our success is enabled by our transformative platform that integrates ground-truth, physics-based simulation with leading-edge AI and machine learning. Looking ahead to 2026, we are poised to scale our impact through new platform enhancements and the commercial launch of our predictive toxicology solution,” said Ramy Farid, Ph.D., chief executive officer of Schrödinger
Full-year net loss shrank to $103.3 million compared to $187.1 million delivered in 2024. Schrodinger bounced to profitability in the fourth quarter of FY25, reporting net income of $32.5 million, compared with a net loss of $40.2 million in the fourth quarter of 2024.
The company also issued impressive 2026 guidance, expecting software revenue to range between $218 and $228 million, representing 10-15% growth. Drug discovery revenue is expected to range between $55 million and $65 million.
Schrödinger, Inc. (NASDAQ:SDGR) is a healthcare technology company that provides a physics-based software platform for molecular simulation, enabling the discovery of novel, high-quality molecules for drug development and materials science. The company’s platform is designed to accelerate research and development (R&D) by predicting molecular properties, reducing the time and cost required to bring new products to market.
3. Nuvation Bio Inc. (NYSE:NUVB)
Nuvation Bio Inc. (NYSE:NUVB) is one of the best cancer stocks to invest in now. On February 9, Nuvation Bio Inc. (NYSE:NUVB) finalized a protocol amendment to an ongoing global SIGMA study of safusidenib. The company is evaluating the efficacy and safety of safusidenib in patients with high-risk or high-grade IDH1-mutant astrocytoma.
The amended protocol expands patient eligibility in the registration portion of the trial. It will also enroll a non-pivotal single-arm cohort to examine the efficacy and safety of safusidenib in chemotherapy- and radiotherapy-naïve patients. The company has already delivered positive Phase 2 trial results, including both astrocytoma and oligodendroglioma.
“These SIGMA protocol updates reflect alignment with U.S. regulators to support the potential approval of safusidenib as swiftly as possible for a patient population that is in dire need of options,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio.
Nuvation Bio Inc. (NYSE:NUVB) has already reiterated its commitment to identifying biomarkers and targeting specific mutations to develop precise therapies. It is part of a broader plan to address critical needs in oncology.
2. Summit Therapeutics Inc. (NASDAQ:SMMT)
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best cancer stocks to invest in now. On February 23, Summit Therapeutics Inc. (NASDAQ:SMMT) reiterated it is progressing with the development of ivonescimab in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). It’s undertaking multiregional Phase III clinical trials.
In addition, the company has engaged GORTEC, a European Head and Neck Oncology and Radiotherapy Group, to activate clinical sites in a phase III clinical study. The trial is to evaluate ivonescimab monotherapy and ivonescimab in combination with ligufalimab, Akeso’s proprietary anti-CD47 monoclonal.
The US Food and Drug Administration has already accepted the company’s Biologics License Application (BLA) filing for ivonescimab in combination with chemotherapy. The company has also partnered with GSK plc to evaluate ivonescimab in combination with B7-H3 and risvutatug rezetecan in multiple solid tumors.
Meanwhile, Summit Therapeutics exited the fourth quarter of 2025 with $713.4 million in cash and cash equivalents and $412.3 million in short-term investments. Meanwhile, net loss for the full year 2025 widened to $347.2 million, or $0.46 a share, from $179.3 million, or $0.24 a share, in 2024.
Summit Therapeutics Inc. (NASDAQ:SMMT) is a Miami-based biopharmaceutical company focused on the discovery, development, and commercialization of oncology therapies to improve patient quality of life and address unmet medical needs. Its lead candidate is ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF for treating solid tumors like non-small cell lung cancer.
1. Janux Therapeutics, Inc. (NASDAQ:JANX)
Janux Therapeutics Inc. (NASDAQ: JANX) is one of the best cancer stocks to invest in now. On February 17, Janux Therapeutics Inc. (NASDAQ:JANX) commenced patient dosing in the Phase 1 study of JANX011. The company has already dosed the first patient in the trial evaluating JANX011 for the treatment of autoimmune diseases.
The candidate drug is designed to enable deep and durable immune reset by targeting the depletion of CD19-expressing B cells in blood and tissue. Designed on the company’s ARM platform, it is intended to deliver sustained target B-cell depletion. The drug has already shown potential to achieve pharmacodynamic effects comparable to those of CAR-T therapies.
“Dosing the first participant with JANX011 marks an important milestone for Janux and the first clinical evaluation of our ARM platform,” said David Campbell, Ph.D., President and CEO, Janux Therapeutics. “While JANX011 is initially being developed for autoimmune diseases, the differentiated immune profile of the ARM platform may also have broader implications across CD19-expressing diseases, including hematologic malignancies.”
Janux Therapeutics, Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company developing novel, tumor-activated immunotherapies to treat cancer by maximizing T-cell targeting while minimizing toxicity. Using its proprietary TRACTr, TRACIr, and ARM platforms, Janux engineers bispecific molecules that selectively activate immune responses against solid tumors.
While we acknowledge the potential of JANX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JANX and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
